Coagulopathy in intensive care Haematological Disorders Coagulation defect, unspecified
Conditions
Interventions
Blood will be taken on enrolment, before and after Fresh Frozen Plasma transfusion or at the end of the study if no transfusion is given. The majority of patients will have central venous access or pe
Sponsors
NHS Blood and Transplant (NHSBT) (UK)
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Admission to a general intensive care unit 2. Prolongation of the PT time by more than 3 seconds beyond the upper limit of the normal range for local hospital within 48 hours of admission
Exclusion criteria
Exclusion criteria: 1. No evidence of active clinical bleeding at the time of enrolment (for example active blood loss through post-operative drains, or clinically significant bleeding, defined as an estimated total cumulative blood loss > 300ml) 2. Warfarin therapy or other treatment dose anticoagulant therapy at the time of enrolment
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Haemostasis will be measured using traditional coagulation tests [ prothrombin time (PT), activated partial thromboplastin time (APTT), platelets, fibrinogen) and the new whole blood techniques of assessing clot formation and breakdown TG, Thrombelastography (TEG) and thromboelastometry (ROTEM). Clotting factor levels, vWF levels, antithrombin, proteins c and s levels will be measured, in cases where there is a disproportionate difference between PT and the newer techniques of measuring coagulopathy. | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. The effect of transfusing FFP will be measured using traditional coagulation tests (PT, APTT, platelets, fibrinogen) and the new whole blood techniques of assessing clot formation and breakdown TG, TEG and ROTEM. 2. The number and severity of clinically significant bleeds will be recorded using a Bleeding Assessment Form | — |
Countries
United Kingdom
Outcome results
None listed